MRNA Stock Eyes Worst Week In 11 Months After June Surge — What’s Ahead?
The pullback appears driven by a mix of profit-taking and cautious Wall Street comments after a whopping 48% rally in June and a smaller 3% rally in May. Moderna confirmed in June that its seasonal flu vaccine candidate, mRNA-1010, remains on track for a regulatory decision by August 5. Earlier this month, CNBC’s Jim Cramer … Read more